Journal article

CIS is a potent checkpoint in NK cell-mediated tumor immunity

Rebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, Jai Rautela, Wei Shi, Eva M Putz, Kimberley Stannard, Jian-Guo Zhang, Charis Teh, Matt Firth, Takashi Ushiki, Christopher E Andoniou, Mariapia A Degli-Esposti, Phillip P Sharp, Caroline E Sanvitale, Giuseppe Infusini, Nicholas PD Liau, Edmond M Linossi, Christopher J Burns, Sebastian Carotta Show all

Nature Immunology | NATURE PUBLISHING GROUP | Published : 2016

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia


Awarded by NHMRC


Awarded by Austrian Science Fund (FWF)


Awarded by AbbVie


Awarded by Bayer PHARMA AG


Awarded by Boehringer Ingelheim


Awarded by Canada Foundation for Innovation


Awarded by Canadian Institutes for Health Research


Awarded by Genome Canada


Awarded by GlaxoSmithKline


Awarded by Janssen


Awarded by Lilly Canada


Awarded by Novartis Research Foundation


Awarded by Ontario Ministry of Economic Development and Innovation


Awarded by Pfizer


Awarded by Takeda


Awarded by Wellcome Trust


Funding Acknowledgements

We wish to thank N. Nicola for helpful comments and discussion, P. Rueda and C. Quillici for technical assistance, Tracy Wilson for generating the wild-type and SH2-mutant CIS expression plasmids, R. Anderson for the E0771.LMB cells, and L. Town, K. Elder, T. Camilleri and J. Sutton for excellent animal husbandry. We are grateful to the staff of the WEHI Bioservices, Monoclonal antibody facility, Flow cytometry facility and Clinical Translational Centre. This work is supported by program and project grants from the National Health and Medical Research Council (NHMRC) of Australia (1027472 to S.C., N.D.H. and G.T.B., 1013667 and 1098960 to M.J.S., 1047903 to G.T.B., 1016647 to J.G.Z., S.E.N. and W.S.A., 1049407, 1066770 and 1057852 to N.D.H., and 1078763 to D.H.D.G.), as well as an NHMRC Independent Research Institute Infrastructure Support scheme grant and a Victorian State Government Operational Infrastructure Scheme grant. N.D.H. is a recipient of a Melanoma Research Grant from the Harry J Lloyd Charitable Trust and R.B.D. is supported by a Leukemia Foundation scholarship. This work was also supported by fellowships from the NHMRC (GNT0461276 to N.D.H., 1058344 to W.S.A., 545952 to D.S.H., 1090236 to D.H.D.G., 1089072 to C. T., Australia Fellowship 1078671 to M.J.S.), the Australian Research Council (G.T.B.) and the Menzies Foundation (N.D.H.). E.M.P. is supported by a Schroedinger Fellowship from the Austrian Science Fund (FWF): J-3635. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer PHARMA AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Canadian Institutes for Health Research, Genome Canada, GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and the Wellcome Trust [092809/Z/10/Z].